Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

huntington disease/fatigue

リンクがクリップボードに保存されます
ページ 1 から 16 結果
Serial high-resolution structural magnetic resonance imaging scans of the brain can now be precisely aligned, with six degrees of freedom (three mutually orthogonal translational and three rotational degrees of freedom around three mutually orthogonal axes), using a rigid-body subvoxel registration

Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Brain-Derived Neurotrophic Factor (BDNF) is the main candidate for neuroprotective therapy for Huntington's disease (HD), but its conditional administration is one of its most challenging problems. RESULTS Here we used transgenic mice that over-express BDNF under the control of the Glial

Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE To establish the effect of the atypical neuroleptic clozapine on chorea, voluntary motor performance, and functional disability in patients with Huntington's disease. METHODS Thirty three patients with Huntington's disease participated in a double blind randomised trial. A maximum of 150

Mechanisms of altered skeletal muscle action potentials in the R6/2 mouse model of Huntington's disease

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Huntington's disease (HD) patients suffer from progressive and debilitating motor dysfunction for which only palliative treatment is currently available. Previously, we discovered reduced skeletal muscle Cl- channel (ClC-1) and inwardly rectifying K+ channel (Kir) currents in

Myopathy as a first symptom of Huntington's disease in a Marathon runner.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
A semi professional marathon runner at risk for Huntington's disease (HD) (43 CAG repeats) developed signs of a slowly progressive myopathy with exercise-induced muscle fatigue, pain, elevated creatine kinase level, and worsening of his running performance many years before first signs of chorea

Circadian-based Treatment Strategy Effective in the BACHD Mouse Model of Huntington's Disease.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Huntington's disease (HD) patients suffer from progressive neurodegeneration that results in cognitive, psychiatric, cardiovascular, and motor dysfunction. Disturbances in sleep-wake cycles are common among HD patients with reports of delayed sleep onset, frequent bedtime awakenings, and excessive

Blue light therapy improves circadian dysfunction as well as motor symptoms in two mouse models of Huntington's disease.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Patients with Huntington's disease (HD) exhibit movement disorders, psychiatric disturbance and cognitive impairments as the disease progresses. Abnormal sleep/wake cycles are common among HD patients with reports of delayed sleep onset, fatigue during the day, and a delayed pattern of melatonin

Clinical aspects of coenzyme Q10: an update.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The fundamental role of coenzyme Q(10) (CoQ(10)) in mitochondrial bioenergetics and its well-acknowledged antioxidant properties constitute the basis for its clinical applications, although some of its effects may be related to a gene induction mechanism. Cardiovascular disease is still the main

Retigabine (ASTA Medica).

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
ASTA Medica is developing retigabine, a carbamic acid ethyl ester and a selective potassium channel opener, for the treatment of complex partial seizures. Phase II trials have commenced [249117], and a multicenter placebo-controlled dosage-finding study has begun in Europe and Australia [392702].

A novel XK gene mutation in a Taiwanese family with McLeod syndrome.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
McLeod syndrome is one subtype of rare neuroacanthocytosis syndromes characterized by misshapen red blood cells and progressive degeneration of the basal ganglia. It is an X-linked recessive disorder with mutation in the XK gene of the Kell blood group system with multisystem involvements.

Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Testosterone deficiency has been reported in patients with Parkinson disease (PD), Alzheimer disease, and Huntington disease. It is not known whether testosterone therapy (TT) in men with borderline hypogonadism and neurodegenerative diseases will be of substantial benefit. Previously, we

A comparison of mood and quality of life among people with progressive neurological illnesses and their caregivers.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The current study was designed to investigate differences in mood and a range of QOL domains among 423 patients and 335 caregivers of people with motor neurone disease (MND), Huntington's disease (HD), Parkinson's, and multiple sclerosis (MS). Patients and caregivers completed an anonymous

A review of creatine supplementation in age-related diseases: more than a supplement for athletes.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Creatine is an endogenous compound synthesized from arginine, glycine and methionine. This dietary supplement can be acquired from food sources such as meat and fish, along with athlete supplement powders. Since the majority of creatine is stored in skeletal muscle, dietary creatine supplementation

Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Tetrabenazine (TBZ) is a monoamine storage inhibitor that was first introduced in the 1970s for the management of hyperkinetic movement disorders. Despite acceptance and usage worldwide, TBZ was only recently approved in the United States for the treatment of Huntington chorea. This

Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
There is now evidence that depression, as characterized by melancholic symptoms, anxiety, and fatigue and somatic (F&S) symptoms, is the clinical expression of peripheral cell-mediated activation, inflammation and induction of oxidative and nitrosative stress (IO&NS) pathways and of central
Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge